That purchase of UNB was pure luck. In fact, I put in the order for 26 cents and I got it at 25 cents.
The energy sector is up big time today and my coal stocks are flying. These I bought at a premium with profits from AMEP, but they are bouncing back. ACI, BTU, and CNX are expensive, but I think that they will be playing a big role in our nation's future energy needs.
Thanks for the preliminary information on UNB. I reacted to it after seeing the following link on molybdenum:
I agree with this Dow 40,000 concept, if the Dow is loaded with precious metals and energy stocks. But that will not happen.
I don't believe the Fed's inflation figures and maybe you know the answer. What would the Dow be if measured in 1970 or 1980 dollars? You and I know that the dollar has been very inflated particularly over the last three decades, so these inflated dollars represent the present Dow level.
Hold on, yes, I believe the Dow will reach 40,000. My second paragraph quelled my doubts. It will be inflated to 40,000 fed by the ingenious Fed dropping dollars out of helicopters.
I agree. What is now hindering a lot of stocks is "naked" shorting and there seems to be no end to it. The following link is a good read; it has many extended links and we, as investors and part of this country's electorate, should be aware of what is going on behind the scenes.
Jagman, I think back near the beginning of September that China was to initiate establishing/adding to its strategic oil supply and then Hurricanes Katrina and Rita hit. So they deferred buying at those high prices. You're correct; they will buy at the lower crude prices and provide that $50 support level.
Swings are important in gas and oil and we are experiencing them now in October. Once $100 oil did not materialize after the hurricanes, that hot money left the energy sector. However, October is historically a soft month for the energy sector, so that added to the downdraft this month. (I just learned of this softness.)
I sold out of that "chop shop" stock, AMEP, and added three coal companies to my portfolio: BTU, ACI, CNX. These are expensive, but have come back a bit, again, with the downdraft of the October market. I stayed with my positions and feel that they will rebound and grow during the winter months, particularly with the high projected natural gas price.
This could be far out, but if there is a thing such as "Peak Oil" and "Peak Gas," then I believe that coal will be a transition energy alternative until other energy sources are developed. BTU (Peabody Energy)is becoming very proactive in making coal "cleaner" and thereby acceptable.
I went to school from 4th to 12th school with the author, Ken Gerbino. If you're interested in precious metals, go to his site and read his commentaries. I have him managing my gold/silver holdings. Just a thought.
I too hope for that solid news from Tandem soon, but I think they are dotting all the i's and crossing all of the t's with that audit. Things have to be exact, if they intend on moving to a higher exchange.
NEW YORK - John McCamant, editor of Medical Technology Stock Letter, recommends buying shares of BioCryst Pharmaceuticals, the Birmingham, Ala.-based developer of small-molecule drugs.
BioCryst (nasdaq: BCRX - news - people ) shares have surged 50% from their low on Friday to their close on Tuesday, at a 52-week closing high of $15.04. The reason for the enthusiasm: BioCryst's influenza neuraminidase inhibitor drug candidate, peramivir, received prominent and positive mention in a New York Times article about how some discarded drug candidates may have new possibilities in treating the H5N1 avian influenza that has broken out in Southeast Asia, which many public health officials fear could develop into a global pandemic. Peramivir was mentioned as one of the most promising drugs.
Three years ago, peramivir failed a Phase III drug trial due to poor bioavailability (the ability of the drug to be absorbed into the bloodstream) in its pill form. BioCryst is now developing an injectable version of the drug, and peramivir has shown some success in fighting avian flu in pre-clinical testing involving cell cultures and in animals.
In 2001, Johnson and Johnson (nyse: JNJ - news - people ), which had been BioCryst's partner in peramivir's early development, pulled out of the program, leaving BioCryst with exclusive rights to the drug's future profits, which could be substantial. Tamiflu, a flu drug from Gilead Sciences (nasdaq: GILD - news - people ) and Roche, had sales of $450 million in the first half of 2005. BioCryst's total sales for the past 12 months totaled $393,000.
In a July 1, 2005 filing with the Security and Exchange Commission, BioCryst said it is "considering various options for the development of peramivir, including whether to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to conduct clinical trials in humans for avian and other viral strains of influenza." It now appears that BioCryst will file the IND by early November.
In the September issue of Medical technology Stock Letter, McCamant says "recent testing has shown that a single intramuscular injection of peramivir is comparable to, or better than, five days of oral treatment with other neuraminidase inhibitors in preventing death from the avian flu virus."
McCamant also notes that the normal procedure for getting FDA approval requires a series of Phase I, II, and III trials, but BioCryst's initial strategy will be focused on obtaining approval to stockpile peramivir under Project Bioshield guidelines, which are much less rigorous.
The government standard for stockpiled drugs is to prove to the National Institutes of Health the safety and efficacy of a drug through two efficacy studies in animals and one safety study in humans. Peramivir has already been tested in nearly 1,000 people, and additional human testing will begin in January.
Reuters reports that BioCryst Chief Executive Officer Charles Bugg said the company had enough peramivir on hand to treat 15,000 to 20,000 people and has already ordered enough raw materials to make enough of the drug to treat up to another million.
"BCRX has a readily scalable manufacturing process in place that could rapidly ramp up to produce 120 million doses per year," says McCamant. "In addition, it appears that peramivir could be up to ten times cheaper than Tamiflu--BCRX estimates a cost in the $1 range per dose versus Tamiflu's expected bulk-discounted cost of $12 per course."
BioCryst has nearly tripled in value since late May, but McCamant says the sharp rise "may only just be the start," and cites the company's small-market capitalization of $304 million. His 18 to 24 month price target is $25, although his buy limit is $12, which is lower than the stock's price (as of Tuesday's close). Buy on pullbacks.
BioCryst lost $22 million in the past 12 months on revenue of $393,000. On the balance sheet, BioCryst has no debt and $1.26 per share in cash, and last month filed an $85 million shelf offering, which will allow it to sell additional shares.
The investment above was recommended in Forbes Newsletters' free Stock of the Week e-mail when BioCryst was trading below McCamant's $12 buy limit.
News would be welcomed; things are now in the doldrums. I believe the entire energy sector is currently undergoing its annual correction.
Part of this correction, however, is compounded this year by the many who have deserted energy, as the $100 oil price they expected did not materialize after Hurricanes Katrina and Rita. In other words, they ran the price up and are now running it down; this has adverse implications on all energy companies.
At the end of next month and into December, I expect a reversal to occur.
Actually the price is holding here until I pick up some more shares.
Seriously though, I was once an auditor at the beginning of my banking career and audit requirements, compliance, et al, have become increasingly challenging over the years and very time consuming. Once that initial audit is completed, subsequent audits will piggyback on the prior ones.
You may be impatient now (as am I), but we will be happy with the results later.
Just my hunch, but once we are on the AMEX, we will be on the radar screens, not only of fellow individual and institutional investors, but we might someday become a take over target as the world's energy sources become more scarce. I think that junior companies will be targeted for growth purposes.
This is all just my opinion, but I have a good feeling for this stock play.
SLW was recommended to me by a broker friend. My experience with this stock has been very positive.
I feel that this stock along with other precious metal stocks will be doing well as the dollar weakens. Its price will continue upward as our trade deficit and federal budget deficit grow. I perceive it to be a good inflation hedge.